Characterization of biofilm formation and the role of BCR1 in clinical isolates of Candida parapsilosis

Eukaryotic Cell

Volumn 13, Issue 4, 2014, Pages 438-451

  Pannanusorn, Srisuda ^a,b   Ramírez Zavala, Bernardo ^c   Lünsdorf, Heinrich ^d   Agerberth, Birgitta ^a   Morschhäuser, Joachim ^c   Römling, Ute ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; FUNGAL PROTEIN; RP 1 PEPTIDE; RP-1 PEPTIDE; VIRULENCE FACTOR;

ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECT; FUNGUS HYPHAE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC COMPLEMENTATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; GENE DELETION; GENE EXPRESSION REGULATION, FUNGAL; GENETIC COMPLEMENTATION TEST; HUMANS; HYPHAE; MICROBIAL SENSITIVITY TESTS; VIRULENCE FACTORS;

EID: 84897464187     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.00181-13     Document Type: Article

References (49)

1. Wisplinghoff H, Bischoff T, Tallent M, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. http://dx.doi.org/10.1086/421946.
2. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R, ECMM Working Group on Candidaemia. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23:317-322. http://dx.doi.org/10.1007 /s10096-004-1103-y.
3. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. 2004. A prospective epidemiological survey of candidaemia in Sweden. Scand. J. Infect. Dis. 36:52-55. http://dx.doi.org/10.1080/00365540 310017447.
4. Maganti H, Yamamura D, Xu J. 2011. Prevalent nosocomial clusters among causative agents for candidemia in Hamilton, Canada. Med. Mycol. 49:530-538. http://dx.doi.org/10.3109/13693786.2010.547880.
5. Spiliopoulou A, Dimitriou G, Jelastopulu E, Giannakopoulos I, Anastassiou E, Christofidou M. 2012. Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series. Mycopathologia 4:219-228. http://dx.doi.org/10.1007 /s11046-011-9498-3.
6. Trofa D, Gacser A, Nosanchuk J. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625. http://dx.doi.org/10. 1128/CMR.00013-08.
7. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int. J. Antimicrob. Agents 38:65-69. http: //dx.doi.org/10.1016/j.ijantimicag.2011.02.016.
8. Finkel JS, Mitchell AP. 2011. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 9:109-118. http://dx.doi.org/10.1038 /nrmicro2475.
9. Frade JP, Arthington-Skaggs BA. 2011. Effect of serum and surface characteristics on Candida albicans biofilm formation. Mycoses 54:e154-e162. http://dx.doi.org/10.1111/j.1439-0507.2010.01862.x.
10. Yoshijima Y, Murakami K, Kayama S, Liu D, Hirota K, Ichikawa T, Miyake Y. 2010. Effect of substrate surface hydrophobicity on the adherence of yeast and hyphal Candida. Mycoses 53:221-226. http://dx.doi.org /10.1111/j.1439-0507.2009.01694.x.
11. Nobile CJ, Schneider HA, Nett JE, Sheppard DC, Filler SG, Andes DR, Mitchell AP. 2008. Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 18:1017-1024. http://dx.doi.org/10.1016/j.cub. 2008.06.034.
12. Nobile CJ, Andes DR, Nett JE, Smith FJ, Jr, Yue F, Phan Q-T, Edwards JE, Jr, Filler SG, Mitchell AP. 2006. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2:e63. http://dx.doi.org/10.1371/journal.ppat.0020063.
13. Ramage G, VandeWalle K, López-Ribot JL, Wickes BL. 2002. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214:95-100. http://dx.doi.org/10.1111/j.1574-6968.2002.tb11330.x.
14. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008. http://dx.doi.org/10.1099/jmm.0.46569-0.
15. Martins M, Uppuluri P, Thomas D, Cleary I, Henriques M, Lopez-Ribot JL, Oliveira RR. 2010. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 169:323-331. http://dx.doi.org/10.1007/s11046-009-9264-y.
16. Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H, Andes DR. 2013. Role of matrix _-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob. Agents Chemother. 57:1918-1920. http: //dx.doi.org/10.1128/AAC.02378-12.
17. Xie Z, Thompson A, Sobue T, Kashleva H, Xu H, Vasilakos J, Dongari-Bagtzoglou A. 2012. Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing. J. Infect. Dis. 206:1936-1945. http://dx.doi.org/10.1093/infdis/jis607.
18. Finkel JS, Xu W, Huang D, Hill EM, Desai JV, Woolford CA, Nett JE, Taff H, Norice CT, Andes DR, Lanni F, Mitchell AP. 2012. Portrait of Candida albicans adherence regulators. PLoS Pathog. 8:e1002525. http: //dx.doi.org/10.1371/journal.ppat.1002525.
19. Nobile CJ, Fox EP, Nett JE, Sorrells SR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR, Johnson AD. 2012. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148:126-138. http://dx.doi.org/10.1016/j.cell.2011.10.048.
20. Ding C, Butler G. 2007. Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation. Eukaryot. Cell 6:1310-1319. http://dx.doi.org/10.1128/EC.00136-07.
21. Ding C, Vidanes GM, Maguire SL, Guida A, Synnott JM, Andes DR, Butler G. 2011. Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans. PLoS One 6:e28151. http: //dx.doi.org/10.1371/journal.pone.0028151.
22. Pannanusorn S, Fernandez V, Römling U. 2013. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses 56:264-272. http://dx.doi.org/10.1111/myc.12014.
23. Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021.
24. Sasse C, Schillig R, Dierolf F, Weyler M, Schneider S, Mogavero S, Rogers PD, Morschhauser J. 2011. The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans. PLoS One 6:e25623. http://dx.doi.org/10.1371 /journal.pone.0025623.
25. Horvath P, Nosanchuk JD, Hamari Z, Vagvölgyi C, Gacser A. 2012. The identification of gene duplication and the role of secreted aspartyl proteinase 1 in Candida parapsilosis virulence. J. Infect. Dis. 205:923-933. http: //dx.doi.org/10.1093/infdis/jir873.
26. Schmitt ME, Brown TA, Trumpower BL. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092. http://dx.doi.org/10.1093/nar/18.10.3091.
27. Rossignol T, Logue ME, Reynolds K, Grenon M, Lowndes NF, Butler G. 2007. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob. Agents Chemother. 51:2304-2312. http://dx.doi. org/10.1128/AAC.01438-06.
28. Brillowska-Dabrowska A, Schön T, Pannanusorn S, Lönnbro N, Bernhoff L, Bonnedal J, Häggström J, Wistedt A, Fernandez V, Arendrup MC. 2009. A nosocomial outbreak of Candida parapsilosis in southern Sweden verified by genotyping. Scand. J. Infect. Dis. 41:135-142. http://dx. doi.org/10.1080/00365540802585301.
29. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun. 70:878-888. http://dx.doi.org/10. 1128/IAI.70.2.878-888.2002.
30. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E. 2010. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 53:208-214. http://dx.doi.org/10.1111/j.1439-0507.2009. 01690.x.
31. García-Sánchez S, Aubert S, Iraqui I, Janbon G, Ghigo J-M, d'Enfert C. 2004. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot. Cell 3:536-545. http://dx.doi.org/10.1128/EC.3.2.536-545.2004.
32. Nobile CJ, Mitchell AP. 2005. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr. Biol. 15:1150-1155. http://dx.doi.org/10.1016/j.cub.2005.05.047.
33. Laffey SF, Butler G. 2005. Phenotype switching affects biofilm formation by Candida parapsilosis. Microbiology 151:1073-1081. http://dx.doi.org /10.1099/mic.0.27739-0.
34. Naglik JR, Challacombe SJ, Hube B. 2003. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67:400-428. http://dx.doi.org/10.1128/MMBR.67.3.400-428.2003.
35. Jung S-I, Finkel JS, Solis NV, Chaili S, Mitchell AP, Yeaman MR, Filler SG. 2013. Bcr1 functions downstream of Ssd1 to mediate antimicrobial peptide resistance in Candida albicans. Eukaryot. Cell 12:411-419. http: //dx.doi.org/10.1128/EC.00285-12.
36. Li F, Palecek SP. 2003. EAP1, a Candida albicans gene involved in binding human epithelial cells. Eukaryot. Cell 2:1266-1273. http://dx.doi.org/10. 1128/EC.2.6.1266-1273.2003.
37. Lewis RE, Lo H-J, Raad II, Kontoyiannis DP. 2002. Lack of catheter infection by the efg1/efg1 cph1/cph1 double-null mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrob. Agents Chemother. 46:1153-1155. http://dx.doi.org/10.1128/AAC.46.4.1153-1155. 2002.
38. Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Marchillo K, Oshel P, Andes D, Palecek SP. 2007. Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo. Eukaryot. Cell 6:931-939. http://dx.doi.org/10.1128/EC.00049-07.
39. Connolly LA, Riccombeni A, Grozer Z, Holland LM, Lynch DB, Andes DR, Gacser A, Butler G. 2013. The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis. Mol. Microbiol. 90:36-53. http://dx.doi.org/10. 1111/mmi.12345.
40. Guan G, Xie J, Tao L, Nobile CJ, Sun Y, Cao C, Tong Y, Huang G. 2013. Bcr1 plays a central role in the regulation of opaque cell filamentation in Candida albicans. Mol. Microbiol. 89:732-750. http://dx.doi.org/10.1111 /mmi.12310.
41. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. 2007. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl. Environ. Microbiol. 73:1697-1703. http://dx.doi.org/10.1128/AEM. 02439-06.
42. Thein ZM, Samaranayake YH, Samaranayake LP. 2007. In vitro biofilm formation of Candida albicans and non-albicans Candida species under dynamic and anaerobic conditions. Arch. Oral Biol. 52:761-767. http://dx. doi.org/10.1016/j.archoralbio.2007.01.009.
43. Tobudic S, Kratzer C, Lassnigg A, Presterl E. 2012. Antifungal susceptibility of Candida albicans in biofilms. Mycoses 55:199-204. http://dx.doi. org/10.1111/j.1439-0507.2011.02076.x.
44. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Che-mother. 46:1773-1780. http://dx.doi.org/10.1128/AAC.46.6.1773-1780. 2002.
45. Melo AS, Bizerra FC, Freymüller E, Arthington-Skaggs BA, Colombo AL. 2011. Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med. Mycol. 49:253-262. http://dx.doi.org/10.3109 /13693786.2010.530032.
46. Odds FC, Brown AJP, Gow NAR. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279. http://dx.doi.org/10.1016/S0966-842X(03)00117-3.
47. Lott T, Kuykendall R, Welbel S, Pramanik A, Lasker B. 1993. Genomic heterogeneity in the yeast Candida parapsilosis. Curr. Genet. 23:463-467. http://dx.doi.org/10.1007/BF00312635.
48. Enger L, Joly S, Pujol C, Simonson P, Pfaller M, Soll DR. 2001. Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis. J. Clin. Microbiol. 39:658-669. http://dx.doi.org/10.1128 /JCM.39.2.658-669.2001.
49. Fanning S, Xu W, Solis N, Woolford CA, Filler SG, Mitchell AP. 2012. Divergent targets of Candida albicans biofilm regulator Bcr1 in vitro and in vivo. Eukaryot. Cell 11:896-904. http://dx.doi.org/10.1128/EC.00103-12.